Over the last three decades, our understanding of the molecular changes associated with cancer development and progression has advanced greatly. This has led to new cancer therapeutics targeted against specific molecular pathways; such therapies show great promise to reduce mortality, in part by enabling physicians to tailor therapy for patients based on a molecular profile of their tumor.
Endogenous optical contrast can provide information about angiogenesis, hypoxia, cell metabolism, and invasion [12] [13] [14] . Optically active contrast agents applied topically prior to imaging can be used to visualize a broader range of molecular changes; these agents have the potential to increase image contrast between neoplastic and healthy tissue thereby facilitating detection of cancer at the earliest possible stages. The ability to non-invasively image the spatial and temporal distribution of multiple biomarkers across a tumor surface also has the potential to improve treatment, through better selection of targeted therapeutic agents, real-time imaging for in situ guidance of tumor margin assessment, and monitoring patient response to treatment without need for biopsy.
Optical molecular imaging systems consist broadly of three components: (1) an optically-active contrast agent targeting a specific biomarker of clinical relevance; (2) a method to safely deliver the contrast agent to the tissue at risk; and (3) an optical imaging system to acquire, process, and interpret resulting images of labeled tissue. Because these tools are low-cost, portable, and can be miniaturized they are capable of expanding access to early detection and improving minimally invasive treatment in a wide variety of urban and rural healthcare settings. However, achieving the potential of this technology requires coordinated efforts in biomarker discovery and validation, design and delivery of contrast agents, and engineering of optical instrumentation. In this paper, we review recent advances in these areas, focusing on advances in imaging agents and delivery systems. More comprehensive reviews of advances in optical instrumentation may be found in [12, 15] . We conclude by discussing the steps necessary to translate optical molecular imaging from a laboratory research tool to incorporation as part of routine clinical examination.
Endogenous Optical Contrast
Optical images carry information about signatures arising from endogenous and exogenous biomarkers [12, 16] . The spatial resolution and field of view of optical imaging systems can be adjusted to interrogate tissue over a wide range of spatial scales; the field of view of widefield optical imaging systems can easily span tens of centimeters, while the spatial resolution of intravital optical microscopy systems can reach subcellular levels.
A number of widefield imaging platforms designed to improve the early detection of neoplasia by imaging endogenous optical properties of tissue are being evaluated in large, multi-center clinical trials.
For example, Curvers et al. developed a tri-modal endoscope to improve the early detection of esophageal neoplasia in patients with Barrett's esophagus. The endoscope combines three widefield optical imaging modalities; the first two modalities, high-definition white light endoscopy and autofluorescence imaging, serve as 'red flag' techniques to identify potentially neoplastic lesions with high sensitivity based on atypical glandular patterns and/or loss of autofluorescence. Suspicious areas are then imaged using narrow-band reflectance imaging to enhance visualization of superficial vasculature features to improve specificity. In a multicenter study of 84 patients with Barrett's esophagus, they compared the sensitivity and specificity of each mode for diagnosis of neoplasia to the gold standard of histopathology [17] . Autofluorescence imaging raised the detection rate of neoplasia from 45% to 90% relative to high definition white light endoscopy; however, autofluorescence imaging was associated with a high false positive rate. The use of narrow band imaging reduced the false positive rate from 81% to 26% relative to autofluorescence imaging.
Similar devices have been developed to identify early neoplastic changes in oral, cervical, and pulmonary mucosa based on changes in endogenous optical properties [14, [18] [19] [20] . In each organ site, neoplastic lesions are typically associated with loss of autofluorescence; areas which exhibit loss of autofluorescence are often clinically occult under traditional white light imaging [14, 20, 21] . In the last few years, a number of widefield optical imaging systems have received FDA approval to augment early detection of neoplastic lesions, including the VELscope (oral), Trimira-3000 (oral), Olympus Lucera (GI), and the Xillix LIFE scope (lung). Still, specificity of widefield imaging remains a significant concern as benign changes such as inflammation can also be associated with loss of autofluorescence [17, [22] [23] [24] .
To address the limitations associated with endogenous contrast, a number of targeted, optically active contrast agents have been developed. These agents are generally comprised of two parts: a targeting moiety and an optically active probe (Figure 1) . Targeted agents have the potential to increase image contrast between normal and neoplastic tissue and to improve the specificity of optical imaging. The targeting moiety is an important determinant of the specificity and sensitivity of the contrast agent. The targeted biomarker must be adequately abundant for detection and sufficiently specific to the particular disease or stage of the disease under examination to yield adequate image contrast. Once the target biomarker has been identified, a targeting moiety must be selected. Antibodies, antibody fragments, and peptides identified from phage display peptide libraries are some of the most commonly used targeting moieties; each class of targeting molecule is associated with different binding kinetics and delivery challenges. In each case, an optically active probe must be conjugated to the targeting moiety, often via an amine, carboxyl, or thiol functional groups present in the targeting protein. The optically active probe provides the ability to visualize the target in a particular imaging modality. Optical probes that have shown promise for molecular imaging include organic fluorophores, metal nanoparticles, nanoshell composites, and semiconductor nanocrystals. Again, each is associated with different delivery challenges and limits of optical detection. Stability, contrast, the potential to image multiple targets, and toxicity are important considerations when selecting both the targeting moiety and the optical probe.
Recent advances in contrast agent design are discussed in the following sections, organized according to the type of optical probe.
Fluorescent Contrast Agents for Molecular Imaging
Organic fluorescent dyes are routinely used as contrast agents in immunohistochemical staining protocols. Because of their small molecular weight, high quantum yield, relatively low cost, and the existence of well-developed conjugation protocols, they represent an ideal optical label for molecular imaging probes. Of particular interest are dyes that fluoresce in the near infrared (NIR) range, where tissue turbidity is lowest and the greatest depth of light penetration can be achieved [25] . Although organic fluorophore-based contrast agents have found use in small animal in vivo studies, clinical application lags behind [26, 27] .
Challenges associated with organic fluorescent dyes include their propensity for photobeaching and the relatively small number of fluorescent dyes which have been approved for clinical use. Another limitation is that optical images of tissues stained with fluorescent contrast agents are highly surfaceweighted even in the NIR, due to light attenuation in tissue; as a practical result, these agents are of most use for imaging lesions near the epithelial surface. Finally, the contrast and sensitivity which can be achieved with contrast agents incorporating organic fluorescent dyes is largely dependent on the choice of biomarker and targeting moiety. Perhaps the most significant challenge with this approach is the difficulty of achieving high target-to-background ratios. The optical signal of targeted fluorescent dyes is largely the same whether they are bound to the targeted biomarker or not; this can limit the maximum target-to-background ratio which can be achieved and can reduce the dynamic range and sensitivity of the agent. [28] [29] [30] . Fluorescently labeled cetuximab, a chimeric anti-EGFR antibody approved for therapy of colorectal and head and neck cancers, was administered by IV to 20 nude mice with human gastrointestinal tumor xenografts for in vivo optical molecular imaging and therapeutic purposes [31] . Tumor tissue was specifically stained but surrounding normal tissue had no detectable signal suggesting this labeled therapeutic antibody has potential as a diagnostic probe.
However, the imaging time window must be optimized, as the target-to-background ratio may remain high if unbound antibody is still circulating after intravenous injection. Studies are ongoing to document whether the fluorescence signal measured in vivo correlates with therapeutic response. In a similar approach, the potential diagnostic use of fluorescently labeled bevacizumab, a humanized monoclonal antibody that binds to vascular endothelial growth factor A, was explored following topical application in resected human tumor specimens and IV administration in nude mice with human colorectal tumor xenografts [32] . Specific labeling was achieved in both model systems and could be documented using a commercially available fluorescence endoscope.
A limitation of antibody-targeted fluorescent contrast agents is the potential immunogenicity associated with the targeting moiety. Chimeric and humanized antibodies have been engineered to decrease the immunogenicity evoked by the murine antibodies initially under investigation. In addition, antibodies are large molecules (~ 150 kDa), and this presents barriers to tissue penetration during IV administration as well as topical application. Engineered antibody fragments are smaller in size and have the potential to improve delivery while maintaining the specificity and lowering production costs [33] .
Peptide Targeted Fluorophores:
Targeting peptides present an attractive alternative to the use of antibodies [34] . Their small size (<10 kDa) reduces barriers to topical delivery and tumor penetration and they are less likely to elicit an immune response [35] . A number of near infrared dyes are commercially available for peptide conjugation. Amine reactive dyes are commonly used to label lysine residues which are relatively abundant in proteins. The targeting specificity of peptides can be compromised by fluorophore labeling; thus, reaction conditions must be optimized for every agent in order to balance the tradeoff between the degree of peptide labeling and retaining target specificity.
Following conjugation, excess dye must be removed, typically through filtration or dialysis, to avoid nonspecific staining. Following intravenous injection, peptides are removed rapidly through renal excretion thereby lowering the background fluorescence but simultaneously creating a very narrow temporal window in which imaging must be performed.
The use of peptide ligands which bind cell surface receptors that are differentially expressed on cancer cells have been explored as targeting moieties for fluorescent contrast agents. For example, epidermal growth factor (EGF) labeled with AlexaFluor647 was used to image epidermal growth factor receptor (EGFR), which is overexpressed in many epithelial cancers [36] . Increased fluorescence signal was observed in neoplastic regions of excised human oral tissue. Compared with normal mucosa from the same patient, an average 2.3-fold increase and 3.8-fold increase in wide-field fluorescence was observed in precancerous and neoplastic specimens, respectively. Similarly, intravenously administered EGF labeled with Cy5.5 was observed to specifically label EGFR positive tumors in mice [37] . Cy5.5-EGF fluorescence was blocked by preadministered unlabeled EGF and an EGFR antibody. However, immunohistochemistry of EGF-Cy5.5 treated tumors showed activation of the EGFR signaling pathway [38] . Before EGF can be used as a diagnostic agent, downstream effects associated with ligand-receptor binding must be considered; there is concern that potential activation and upregulation of EGFR associated with ligand binding could potentially enhance cancer progression. Traditional phage display techniques identify peptides that target cancer-associated antigens but are unable to eliminate peptide sequences that will ultimately fail due to in vivo barriers. In vitro phage display is unable to test peptides against physical delivery barriers, opsonization and pharmacokinetics, issues that hinder the translation of peptides to the clinic. The screening of phage libraries in living organisms after intravenous injection identifies peptides which are able to reach and bind to the target.
Kelly et al. demonstrated the ability of this approach to rapidly identify phage bearing target peptides for molecular specific imaging [42] . Similarly, in vivo phage display followed by a micropanning assay was used to identify a ligand specific to human PC-3 prostate carcinoma xenografts in a murine model [43] . After labeling with an NIR fluorophore, the intravenously administered contrast agent yielded a tumor-to-muscle fluorescence ratio of 30 in wide-field fluorescence imaging.
The avidity of peptide targeted contrast agents may be optimized by increasing the number of peptide targeting moieties conjugated to each optical label. Cheng varied the number of RGD targeting peptides conjugated to Cy5.5 dye and examined the resulting contrast agent avidity and tumor targeting efficacy in a subcutaneous xenograft animal model. As the number of targeting peptides per dye molecule was increased from one to four, avidity improved by approximately 3-fold in a cell culture model. The ratio of fluorescence signal from tumor-to-normal tissue increased moderately for the Cy5.5-conjugated RGD tetramer compared to the monomer and dimer. While all three probes were visualized, the tetramer displayed the highest tumor uptake and tumor to background ratio up to 4 hours post injection [44] .
Similarly, phage display techniques were used to identify peptides targeting a prostate biomarker, hepsin; multiple hepsin targeting peptides were conjugated fluorescent nanoparticles in an attempt to improve avidity and pharmacokinetics [45] . Conjugation of 11 targeting peptides per nanoparticle resulted in greater than 10-fold increase in fluorescence signal compared with a peptide-only control.
Fluorescent Probes of Metabolic Activity:
Alteration of cellular metabolism is one of the hallmarks of cancer [46] . Indeed, the use of FDG as a contrast agent for PET, is based on the increase in uptake of deoxy-glucose associated with tumors. Fluorescently labeled fructose and deoxy-glucose have been developed for in vivo optical imaging of cancer metabolism. Fructose labeled with 7-nitro-1,2,3-benzadiazole (1-NBDF) and Cy5.5 (1-Cy5.5-DF) were both shown to be taken up in breast cancer cell lines; however, while the uptake of 1-NBDF was specific to Glut5, a fructose transporter that is commonly expressed in cancers, that of 1-Cy5.5-DF was not [47] . Similar results were observed in studies with fluorescently labeled deoxyglucose. Uptake of 2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose) was specific to GLUT transporters and was competitively inhibited in the presence D-glucose. In contrast, uptake of Cy5.5-DG was not specific to the GLUT transporters [48] .
Other studies have explored the use of topically delivered 2-NBDG in cell culture and excised normal and neoplastic human oral tissue. Neoplastic oral tissue was associated with higher uptake of the 2-NBDG, leading to a 3.7 fold increase in fluorescence signal compared to normal tissue [49] . A similar increase in fluorescence signal was observed in excised malignant breast tissue that was topically treated with 2- protease activated near infrared dye, to improve the signal to background ratio of metastatic tumor foci in a murine xenograft model of peritoneal carcinomatosis by a minimum of 3.5 fold relative to white light imaging [53] . Prosense680, a similar protease activateable dye, was imaged in vivo to effectively monitor response of colon polyps to anti-TNFα therapy via in a murine model [54] . While initial results are encouraging, potential limitations of smart probes include slow uptake, low target-to-background ratios, and uncertain specificity. In addition to protease-activatable imaging probes, smart probes designed to image pH, reactive oxygen species, hypoxia, and other chemical changes are also available [55] .
A second class of smart probes is based on the use of cell-penetrating peptides conjugated to fluorescent labels; cell-penetrating peptides such as polyarginine can efficiently deliver fluorescent cargo inside cells. Cell uptake can be blocked if the labeled cell penetrating peptide is fused to an inhibitory domain containing negatively charged residues. Such fusions have led to a new class of activateable cell penetrating peptides (ACPPs); in an ACPP, the labeled cell penetrating peptide is fused to an inhibitory domain via a peptide-cleavable linker. The linker is cleaved upon exposure to proteases, and the CPP facilitates membrane binding and uptake in tumor cells in cell culture, in animal models, and in resected human tumors [56, 57] . Cultured cells labeled with ACPPs showed more than a 10-fold increase in fluorescent signal upon linker cleavage; mice xenografted with human tumor cells secreting MMP-2 and -9 showed two to three fold increase in fluorescence relative to normal tissue. Conjugation of ACPPs to dendrimers (ACCPDs) improves intravenous delivery of the contrast agent to the target by reducing uptake in skin, cartilage and kidney relative to free ACPPs. The ACCPDs colocalized with the tumor and resulted in 10-fold fewer residual tumor cells at the surgical site after image-guided surgery compared to surgery with no molecular imaging-based guidance. Fluorescence signal remaining after surgery was able to identify small pieces of residual tumor which could be resected after the initial surgery, resulting in improved survival with ACPPD-imaging guidance compared to standard surgery without guidance (Figure 3) . Molecular beacons are another class of smart fluorescent probes designed to image changes in gene expression. Molecular beacons consist of a short sequence of nucleic acid, complementary to the target mRNA to be detected, linking a fluorophore (donor) and a quencher in a particular conformation [58] . In the absence of target mRNA, the beacon is design to self-hybridize in a stem-loop structure so that fluorescence is quenched. When the target mRNA is present, the beacon is designed so that kinetics favor hybridization to the target; hybridization induces conformational change that results in a fluorescence signal. Due to the intracellular location of the target mRNA, the use of molecular beacons relies on being able to deliver contrast agent inside cells of interest. The simultaneous use of molecular beacons and antibody targeted fluorescent dyes has been recently demonstrated to recognize mouse carcinoma stem cells; a beacon was designed to recognize Oct-4 mRNA, an intracellular, transcription factor regulating differentiation, while an antibody targeted dye was used to label SSEA-1, a cell surface protein specific to stem cells. Using the combination of dyes, undifferentiated stem cells could be distinguished from differentiated cells during flow cytometric analysis [59] . The combined detection of intracellular and surface protein markers appears to be a promising approach for highly sensitive and specific detection of neoplastic cells.
Nanoparticle Based Contrast Agents for Molecular Imaging
Plasmonic Nanoparticles: Metallic nanoparticles, usually made of gold or silver, scatter light with remarkable efficiency by virtue of their strong surface plamson resonance. The potential of metallic nanoparticles as optically interrogatable biological labels has led to development of a variety of novel applications in bioanalytical chemistry with unprecedented sensitivity [60] [61] [62] [63] [64] [65] [66] [67] . Typical scattering cross sections of metal nanoparticles greatly exceed the absorption cross section of fluorescent dyes [68] and of fluorescent proteins [69, 70] . The photo-stability, water solubility, and non-toxicity of gold nanoparticles make these probes advantageous for biological imaging. Conjugation strategies to attach targeting or delivery moieties are well developed [71] [72] [73] [74] .
The development of gold nanoparticle-based contrast agents has given rise to new opportunities in optical imaging of cells and tissues; agents have been developed using gold-based nanoparticles with various geometries, including nanoshells [75] [76] [77] , nanorods [78, 79] , and nanocages [80] . Gold nanoparticles can provide optical contrast via either absorption, scattering, or luminescence; the surface plasmon resonance peak of gold nanoparticles is strongly influenced by particle size, shape, material composition, and inter-particle spacing, and can be tuned to the near infrared spectral region (700-850 nm), where tissue is the most transparent [81] .
It has been demonstrated that targeted gold nanoparticles can be used to provide high contrast images of cancer cells using a variety of optical modalities to measure light scattered by the nanoparticles, including reflectance confocal microscopy [72, 82] , dark-field microscopy [83] , phase-sensitive optical coherence tomography [84] , and photoacoustic imaging [85, 86] .
The concept of plasmon coupling of gold nanoparticles has been explored extensively for molecular imaging of carcinogenesis [72, 86, 87] . A number of cancer-related targets exist as closely spaced hetero-and homo-dimers; the epidermal growth factor receptor (EGFR) is a prime example. Binding of the EGF ligand induces EGFR dimerization and receptor aggregation in the plasma membrane. Receptor mediated assembly of EGFR-targeted spherical gold nanoparticles on the cell membrane can result in a dramatic spectral shift of more than 100 nm [87] ; this allows highly sensitive detection of labeled cells, even in the presence of single unbound gold bioconjugates. This plasmon coupling has also been used to monitor EGFR trafficking dynamics within the cell. Upon ligand binding, membrane-bound EGFR elicits growth-promoting signals; this signaling continues after internalization of activated receptor in early endosomes, ceasing after entry into lysosomes. As seen in Figure 4 , the scattering spectrum of EGFRtargeted nanoparticles shifts from green to yellow to red as the receptor tracks from the cell membrane, to early endosomes, and to late endosomes/multivesicular bodies [88] .
Composite nanoparticles can also provide contrast for optical imaging, as well as other traditional medical imaging modalities. Nanoroses are small nanoclusters, approximately 30 nm in diameter, composed of approximately 70 gold coated iron oxide particles that display intense NIR absorbance. A dextran coating facilitates uptake by macrophages. The utility of dextran-coated nanoroses for imaging macrophages was explored in cell culture and in a rabbit model of atherosclerosis; nanorose labeled and unlabeled macrophages could easily be distinguished using darkfield microscopy. Moreover, the strong NIR absorption coefficient of the nanoroses provides the potential for image-guided photoablation therapy [89] . Gold nanocages are hollow, porous nanostructures composed predominately of gold and created by reducing gold onto a silver nanocube template. Gold nanocages are typically less than 100 nm in size and have been explored as contrast agents for optical coherence tomography (OCT) and photoacoustic tomography (PAT) [90] .
Gold nanorods exhibit intense two-photon luminescence, which can also provide a source of signal for optical imaging in tissue. Two photon imaging of tissue phantoms treated with 50 by 15 nm gold nanorods functionalized with EGFR antibodies increased intensity by three orders of magnitude compared to cellular autofluorescence with 760 nm excitation [91] .
Contrast agents based on gold nanoparticles have potential for in vivo use, with topical or systemic delivery. The inherent biocompatibility of gold implies such agents can be used directly in vivo without the need for protective layer growth. In fact, long term treatment of rheumatoid arthritis utilizes gold is performed without any deleterious bioeffects [92] (dose of 1.2-1.8 g/year for >10 years). It has been estimated that between a few hundred micrograms to a few milligrams of gold would be required for a diagnostic procedure [72] . This is thousands of times less than the threshold for any side effects detected in clinical practice [93] [94] [95] . However, the in vivo toxicology of metallic nanoparticles is dependent on particle size, shape, and surface chemistry [96] . Alternatively, other types of metallic nanoparticles may be used as optical contrast agents, but ease of synthesis and biocompatibility concerns are limiting factors. For example, silver nanoparticles exhibit higher extinction coefficients and higher signal but are not as stable or biocompatible in comparison to gold nanoparticles [97] .
Plasmonic Nanoshells: Metallic nanoparticles with a dielectric core/metallic shell composition have been explored extensively as contrast agents for molecular imaging. In particular, the optical resonance of nanoshells with a silica core and thin gold coating can be tailored over a broad spectral range by simply changing the core size and the core to shell ratio. Optimizing nanoshells to have peak scattering in the NIR region imparts the highest imaging depth. The large optical cross section of nanoshells is especially valuable for imaging modalities like OCT and confocal reflectance microscopy. Alternatively, for therapeutic purposes, nanoshells may be optimized to absorb light in this region for use in the photothermal ablation of cancers. Nanoshells targeted to human epidermal growth factor receptor 2 (HER2) have been used for dark-field and reflectance confocal imaging of HER2 positive human breast carcinoma cells in vitro and ex vivo human tissue sections [77, 98, 99] . NIR irradiation induced heating of these antibody targeted nanoshells resulting in photothermal ablation of cells bound to nanoparticles [77] .
Nanoshell composition can be altered to reduce particle outer diameter while retaining peak scattering in the NIR. For example, gold-gold sulfide nanoparticles (40nm) targeted to HER2 which are smaller than silica-gold nanoshells (120-150nm) have also been used for photothermal ablation and multiphoton imaging [100] . Multi-layer, composite spherical nanoparticles have been designed to further optimize optical properties for optical imaging and therapeutic purposes [74] . By altering the composition and thickness of three layered nanospheres, ultra sharp resonance peaks are possible which could allow for multiple targets to be imaged simultaneously [74] .
Semiconductor Nanocrystals: Quantum dots are semiconductor nanocrystals with diameters smaller than the Bohr excitation diameter (2-10nm) . The size-dependent optical properties are due to quantum confinement of electrons and holes. Quantum dots also exhibit improved brightness due to their high extinction coefficients that are an order of magnitude higher than most fluorescent dyes. In addition, these particles have improved photostability compared to organic fluorophores, and their broad excitation bands and narrow emission spectra facilitate the simultaneous labeling of multiple biomarkers. Particle size and composition can be varied to emission properties. Additionally the need for an external excitation source may be eliminated with particular quantum dots.
To date, the use of traditional quantum dots containing cadmium selenide or cadmium sulfide for in vivo imaging has been limited to animal studies due to the toxicity of cadmium [101] . The clinical applicability of these agents is severely impeded by these toxicity concerns. Rare earth nanocrystals may serve as a biocompatible alternative to cadmium based nanocrystals. Kumar et al. used a fluoride nanomatrix (NaYF 4 , 20-30nm) doped with rare-earth ions for optical and magnetic resonance imaging, respectively. Particles were further modified with a targeting antibody, anti-claudin-4, to prove the targeting abilities [102, 103] . Similarly Y 2 O 3 nanocrystals doped with fluorescent Eu 3+ and paramagnetic GD 3+ and conjugated to folic acid were created through an all-aqueous wet-chemical process to yield a targeted, water soluble and biocompatible agent for in vitro testing [103] . Self-illuminating quantum dot conjugates were created by conjugating a mutant of the bioluminescent protein Renilla reniformis luciferase to carboxylate-presenting quantum dots. These particles are luminescent due to bioluminescent resonance energy transfer and have been used for in vivo imaging [104] .
Multi-Modal Contrast Agents
While optical molecular imaging offers many benefits, one of its primary limitations is the relatively limited depth of penetration, especially in comparison to other molecular imaging modalities such as ultrasound and MRI. To address this limitation, several groups have designed targeted contrast agents which are active in multiple modalities, such as optical and magnetic resonance [11, [105] [106] [107] [108] [109] .
Integrating multiple modalities can result in a technique which enables deep tissue imaging with a traditional imaging modality to identify suspicious areas, together with a companion optical modality to interrogate these suspicious regions with higher spatial resolution to more precisely determine tumor location, monitor systemic particle distribution or to improve surgical margin planning. The use of multimodal particles to track of stem cells in vivo exemplifies how whole body imaging using traditional modalities (MR) can be combined with high resolution optical imaging to provide new capabilities that may ultimately be useful to improve diagnosis or to monitor targeted therapeutics [110] .
MR contrast agents may be classified according to whether they affect T1 and T2 relaxation times. For many multi-modal probes, gadolinium is used for T1 weighted imaging and iron oxide is often used for T2 weighted imaging. For example, the use of gold-coated iron oxides for combined optical/T2-weighted MR imaging was demonstrated by a number of groups [105] [106] [107] . In another example, mesoporous silicon was loaded with quantum dots and single-walled carbon nanotubes to enable optical and MR imaging, respectively [108] . These mesoporous silicon containers facilitate transport of the contrast agents through the vascular system. Activateable cell penetrating peptides labeled with Cy5 and gadolinium have been combined to enable optical and T1-weighted MR imaging, respectively [109] . A single injection of ACPP dendrimers labeled with Cy5 and gadolinium enabled pre-and post-operative T1-weighted MR imaging, in addition to intraoperative fluorescence imaging [57] .
More recent strategies enable the combination of traditional MR imaging together with both widefield and high-resolution optical approaches. This is facilitated by the development of a nanoprobe composed of an iron oxide core with a dielectric polymer coating and a gold nanoshell, allowing for MRI, optical microscopy, and photoacoustic imaging [111] . After conjugation to targeting ligands, these all-in-one nanostructures are envisioned for use in non-invasive imaging, molecular diagnosis and photothermal treatment of diseases such as cancer. The ability to use the same particle for multiple imaging techniques is advantageous due to the reduced amount of foreign material required, time saved, and increased information made available.
Optical agents may also be combined with nuclear probes to create another class of multimodal imaging agents. Nuclear imaging modalities, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), enable whole body imaging with high sensitivity. Similar sensitivities for optical and nuclear imaging allow for straightforward design and application of multimodal probes. The radioactive component of the agent may be used to provide data on probe biodistribution and clearance, while the optical component provides a clinician the ability to visualize the target in real time during surgical or endoscopic procedures. The addition of a positron-emitting radionuclide and a NIR fluorophore to trastuzumab (anti HER2 antibody) allowed for identification of not only primary tumors but also metastases in mouse model in vivo [112] .
Delivery of Molecular Imaging Agents
To obtain optical molecular images which reflect changes in biomarker expression requires the ability to deliver contrast agent to cells and tissues of interest, as well as the ability to wash away unbound contrast agent. Two primary routes of administration exist for delivery of imaging agents: topical application and intravenous (IV) injection. Topical application is only appropriate for certain epithelial tissues, but provides some distinct advantages in these cases. Typically smaller amounts of contrast agent are required for topical application; this reduces potential toxicity and clearance concerns associated with IV injection. However, achieving sufficient epithelial permeation of topically applied contrast agents is still a major barrier, especially for larger nanoparticle-based agents. IV delivery can help enhance contrast agent accumulation in tumors via the enhanced permeability and retention (EPR) effect. However, IV delivery typically requires higher dosages of contrast agents and can lead to higher non-specific background signal.
The major barriers to delivery are shown in Figure 5 . Topically applied contrast agents must permeate tight junctions in the epithelium and in some cases a tough, protective keratinized epithelium further hampers delivery. In contrast, agents administered through IV injection must evade degradation and the immune system to reach the target organ. IV administered agents must then localize to the area of interest and leave the circulatory system by passing through endothelial tight junctions. If the IVadministered contrast agent target epithelial cells, they must also be transported through any stromal barriers. Additionally, cytoplasmic-and nuclear-targeted agents delivered via either mechanism must also traverse the cell and nuclear membranes, respectively, to reach the intended target.
The tight junctions of the epithelium serve as a barrier to exclude foreign agents so crossing this delivery barrier is not trivial. Chemical permeation enhancers such as Triton-X and modified chitosan have been used to improve permeation in excised tissues [113] [114] [115] . Alternatively, pulsed ultrasound has been used to enhance permeation of 20 nm particles into the core of MCF-7 breast cancer spheroids compared to those not exposed to ultrasound [116] . These results show the potential for increasing delivery of imaging and therapeutic agents to tumor tissue and the effect of particle properties on penetration.
Thick keratinized surfaces are not affected by many permeation enhancers and alternatives are needed for topical delivery of contrast agents to keratinizing epithelial tissues.
Contrast agent design and modification is especially important for agents administered intravenously, as they must evade the immune system and avoid degradation. Size, shape, and surface chemistry are peptide sequence to the surface of the particle [73] . The actin antibody targets the nanoparticle to a specific structure in the cell, while the TAT portion of the peptide enables endocytosis of the particles, and the HA2 disrupts the endosomal lipid membrane enabling endosomal escape to the cytosol. Kang et al. used the nuclear localization signal (NLS) peptide to target gold nanoparticles to the nucleus causing cytokinesis arrest and resulting in the apoptosis of cancer cells in vitro [117] . A NLS was also used by
Oyelere et al. to improve delivery to the nucleus in vitro [118] . However, these particular particles will likely face other barriers following intravenous delivery. The size of these particles would hinder intravenous delivery due to retention in the blood pool followed by uptake in the liver [119] .
Conclusions
Cancer is the second greatest cause of mortality in the world. There are important unmet clinical needs, including: (1) more effective techniques to screen the general population to identify individuals at high risk for harboring early disease; (2) tools to detect early neoplastic lesions in patients at risk; (3) approaches to more effectively guide treatment of these early lesions.
The optical molecular imaging systems and agents described in this review hold the potential to image the morphologic, functional, and molecular properties of early neoplastic lesions with improved resolution over currently used clinical technologies. To date, a number of optical probes, ranging from organic fluorophores to plasmonic nanoparticles have been developed to fulfill this need and are at various stages of clinical translation. While the small size of organic fluorophores facilitates delivery of such dyes, they are subject to photobleaching and may not achieve sufficient target-to-background ratios for clinical utility. Smart fluorescent probes can improve the target-to-background ratio, but concerns about specificity and low target signals are barriers which must be overcome. Plasmonic nanoparticles and nanoshells and other nanoparticle-based imaging agents offer an attractive alternative to fluorescent dyes, due to the modifiable surface chemistry and the ease with which therapeutic modalities (e.g. photothermal ablation) can be combined. However, the comparatively large size of these particles presents an increased number of barriers to in vivo delivery. An important barrier to translation of all these agents is the challenge associated with obtaining regulatory approval necessary to initiate clinical testing. However, as new biomarkers continue to be discovered and validated, and low-cost, highly sensitive, multi-modal optical imaging systems reach clinical application, there is a growing opportunity to evaluate whether targeted optical contrast agents can help meet the clinical needs of early cancer detection.
Future Perspective
When appropriately validated, these technologies can have impact current clinical practice in the short term, by facilitating screening for and early detection of cancer and its precursors at a time when treatment is most effective. Through early detection and guidance of therapy, optical molecular imaging of cancer has the potential to reduce cancer morbidity and mortality. Because these tools are low-cost and portable they are capable of expanding access to cancer screening and early detection. At the same time, these techniques can be used to study the molecular processes associated with carcinogenesis in vivo in humans. In particular, they provide the ability to directly image the biology of invasion and to study host response serially over time. This knowledge can be used to change future clinical practice. In the future, integrated optical molecular systems can be used alone, or in combination with more traditional imaging technologies, to identify lesions at high risk of progression based on molecular, functional, and phenotypic markers. This knowledge can be used to select the most appropriate choice of therapeutic agent. Finally, the ability to image molecular features of neoplasia can be used to provide a rapid molecular assessment of response.
Executive Summary Molecular Optical Imaging Optical molecular imaging combines advances in optical imaging with targeted, optically active contrast agents to enable non-invasive, real-time monitoring of the molecular changes associated with cancer development and progression. Low-cost optical imaging systems are available to acquire optical molecular imaging with a wide range of fields of view and spatial resolution, spanning the whole organ to the sub-cellular levels. Targeted, optically active contrast agents enable optical imaging of many biomarkers of cancer, associated with the initiation, development, and progression of neoplastic lesions.
Molecular Markers and Targeting
Advances in biomarker discovery and validation have been used to identify targeting moieties to label cancerspecific targets. Antibodies, antibody fragments, peptides, aptamers, and small molecules are being explored as potential targeting moieties for optically active contrast agents. Fluorescent Dyes Fluorescent dyes possess many attractive properties as optical labels for use in optical molecular imaging system: they have small molecular weight, high quantum yield, relatively low cost, and there are many conjugation protocols available to attach targeting moieties. However, the depth of tissue imaging which can be achieved using fluorescence based contrast agents is one limitation. Fluorescently labeled glucose derivatives allow for high resolution, real time visualization of changes in cell metabolism. Smart fluorescent probes produce signal only in the presence of target, thereby lowering non-specific background and improving specificity Nanoparticles Metal nanoparticles can provide optical contrast via either absorption, scattering, or luminescence The surface plasmon resonance peak of gold nanoparticles is strongly influenced by particle size, shape, material composition, and inter-particle spacing, and can be tuned to the near infrared spectral region. Nanoshells, comprised of a metal shell and dielectric core, can be tuned over a broad range by varying the core:shell ratio and overall particle size for imaging and photothermal ablation purposes. Rare earth nanocrystals provide a biocompatible alternative to traditional cadmium-based quantum dots.
Multimodal Agents
Multimodal agents have been developed to enable simultaneous imaging with traditional medical imaging modalities and optical modalities. Integration of multiple modalities can result in the ability to image deep tissue with a traditional imaging modality to identify suspicious areas; these areas can then by interrogated with higher spatial resolution to more precisely determine tumor location with a companion optical modality. Delivery Two primary routes of administration exist for delivery of optical molecular imaging agents: topical application and intravenous (IV) injection. Both routes of administration are riddled by major delivery barriers, which is an obstacle to the translation of these technologies. Delivery to cytoplasmic and nuclear targets adds an additional level of complexity but various peptides have improved intracellular delivery. 
